Lilly Oncology Taking 'Aggressive' Position

Posted: Updated:
(Image of Sue Mahony courtesy of Eli Lilly and Co.) (Image of Sue Mahony courtesy of Eli Lilly and Co.)

The president of Lilly Oncology says the company has a "strong base" of existing and potential treatments to fuel a new strategy for its cancer-fighting pipeline. During an earnings call with investors Tuesday morning, Sue Mahony said the company's oncology unit will be more aggressive, particularly when it comes to potential treatments in earlier stages "that clear a high bar." Officials say Lilly Oncology will sharpen its focus on 10 internal assets, seven of which are currently in the pipeline.

Additionally, Mahony says, Lilly Oncology could continue to connect with other drug makers on partnerships to help drive treatments to market like one signed with Merck & Co. Inc. (NYSE: MRK) earlier this year. The goal, she says, is to boost business development. "Specifically, we will actively pursue assets that combine rationally with our existing products, serve as new potential foundational agents and enable new immuno-oncology breakthroughs," Mahony said. "The good news is that there is a lot of external innovation in oncology, and we intend to be much more active in this space to ensure we have a competitive pipeline going forward."

During a retooling of its business units announced earlier this year, Mahony stayed on as a senior vice president and as president of Lilly Oncology.

Senior Vice President of Global Development and Medical Affairs Levi Garraway, who joined the company in January, says Lilly Oncology is positioned for a "remarkable" opportunity. He says "the vast majority of our internal R&D dollars" will now be focused on the aforementioned seven early-to-mid-stage assets in its oncology pipeline. One potential treatment, Abemaciclib, is awaiting regulatory approval, while several others are in the first, second or third phases of the development process. "We are giving ourselves flexibility to bet more aggressively on portfolio assets with the highest foundational potential," Garraway said, "while de-risking others externally, and importantly, making room to bring external innovation into our oncology portfolio."

During its second quarter earnings report Tuesday, Lilly detailed profit of more than $1 billion, a 35 percent increase from the same period a year earlier, and it revised previous full-year research and development investment expectations to a range of $5 billion to $5.2 billion.

Lilly Oncology President Sue Mahony says the company could continue to connect with other drug makers on partnerships to help drive treatments to market.
  • Perspectives

    • Increasing Women Leaders in Companies and Associations

      As members of an industry largely populated by male professionals, we see firsthand the need for more diversity. As Katie Culp, president of KSM Location Advisors, noted in a recent blog, diversity leads to better business decisions.



Company Name:
Confirm Email:
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections


  • Most Popular Stories

    • Valpo Taking 'Difficult' Actions Involving Law School

      Valparaiso University says its law school is facing "severe financial challenges," deeming the 130-year-old program "financially unsustainable for the foreseeable future." The administration has decided to suspend first-year law school class admissions next fall and the university is exploring alternatives for the future, including affiliating the law school with another institution or relocating it to a market with "perceived greater demand."

    • Salesforce Unveils Indy Training Program

      Salesforce (NYSE: CRM), which in May said it would add 500 new local apprentices by 2020 in Indianapolis, is launching Salesforce Pathfinder Training in the city. The company says the program will give participants skills and business training they need to become administrators or developers in the Salesforce ecosystem, which it calls two of the hottest jobs in tech. Veterans, professionals looking to re-enter the work force and youth who are not working or in school will...

    • 'Stay-at-Home Economy' Fueling Terre Haute Startup

      The e-commerce boom and popularity of companies like Birchbox are driving growth for a Terre Haute-based manufacturer. BoxUp Chief Executive Officer Curt Stephens says the "stay-at-home economy" offers unlimited potential for the year-old business with a growing staff of nine. The Subscription Trade Association estimates the industry's current value at $5 billion. BoxUp offers custom boxes and designs in quantities from 12 to 5,000 to customers including Hoosier...

    • Opioid Withdrawal Treatment Lands FDA Clearance

      The U.S. Food and Drug Administration has given clearance for a medical device developed in Indiana to help treat symptoms of opioid withdrawal. The device, known as the NSS-2 BRIDGE, was created by Innovative Health Solutions Inc. in Versailles.

    • Construction Begins on $25M Assisted Living Facility

      Officials in Noblesville have broken ground on a $25 million assisted living and memory care facility. The four-story, 105,000-square-foot Heritage Woods of Noblesville will include 124 studio and one-bedroom apartments and create nearly 80 full-time and part-time jobs.